C (max) and t (max) verification using Fibonacci sequence and absorption rate
- PMID: 22797869
- DOI: 10.1007/s13318-012-0101-1
C (max) and t (max) verification using Fibonacci sequence and absorption rate
Abstract
The aim of this study was to verify the values of maximal observed concentration (C max,obs) and the time, at which maximum concentration is observed (t max,obs) using the analysis of the absorption rate constant (k ab). It focused on the changes in concentration over time (C-T) for drugs, for which several peaks of concentration occur. In addition, the attempt was made to use Fibonacci sequence to facilitate the visual analysis of the dynamics in changes of concentration on C-T graphs. The analyses were conducted with the use of three hypothetical data groups (groups I, II and III), which had distinct C-T profiles, and with the in vivo data form healthy subjects (n = 10) taking part in a bioequivalence study, who was given a single oral dose of topiramate (100 mg). The comparison of hypothetical and real in vivo data demonstrated that for the C-T curves, in which there are several peaks of concentration C max,obs and t max,obs values can easily be miscalculated when the increase in concentration is not properly related to the appropriate absorption phase (63.2, 87.50, 96.88 %). It was also demonstrated that the data transformation with the use of Fibonacci sequence exposes slight differences in the observed concentration values in a semi-logarithmic scale. The results of this study show that in case of C-T curves with several peaks of concentration, the verification of C max and t max data obtained taking into account different absorption phases enables more precise evaluation of these parameters.
Similar articles
-
Bioequivalence of single 100-mg doses of two oral formulations of topiramate: an open-label, randomized-sequence, two-period crossover study in healthy adult male Mexican volunteers.Clin Ther. 2009 Feb;31(2):411-7. doi: 10.1016/j.clinthera.2009.02.001. Clin Ther. 2009. PMID: 19302913 Clinical Trial.
-
Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.Epilepsia. 2011 Oct;52(10):1877-83. doi: 10.1111/j.1528-1167.2011.03183.x. Epub 2011 Jul 19. Epilepsia. 2011. PMID: 21770925 Clinical Trial.
-
Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.Curr Med Res Opin. 2010 Jun;26(6):1355-62. doi: 10.1185/03007991003740861. Curr Med Res Opin. 2010. PMID: 20377319 Clinical Trial.
-
Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456631
-
Topiramate: pharmacokinetics and pharmacodynamics.Can J Neurol Sci. 1998 Aug;25(3):S3-5. doi: 10.1017/s031716710003482x. Can J Neurol Sci. 1998. PMID: 9706732 Review.
Cited by
-
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.Clin Pharmacokinet. 2019 Jul;58(7):911-926. doi: 10.1007/s40262-019-00736-6. Clin Pharmacokinet. 2019. PMID: 30675694
-
Food-Drug Interaction between the Adlay Bran Oil and Drugs in Rats.Nutrients. 2019 Oct 15;11(10):2473. doi: 10.3390/nu11102473. Nutrients. 2019. PMID: 31618937 Free PMC article.
-
Beverage-Drug Interaction: Effects of Green Tea Beverage Consumption on Atorvastatin Metabolism and Membrane Transporters in the Small Intestine and Liver of Rats.Membranes (Basel). 2020 Sep 14;10(9):233. doi: 10.3390/membranes10090233. Membranes (Basel). 2020. PMID: 32937767 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources